Pine Valley Investments Ltd Liability Co Cuts Stock Holdings in Pfizer Inc. (NYSE:PFE)

Pine Valley Investments Ltd Liability Co lowered its stake in Pfizer Inc. (NYSE:PFE) by 4.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 152,710 shares of the biopharmaceutical company’s stock after selling 7,539 shares during the period. Pine Valley Investments Ltd Liability Co’s holdings in Pfizer were worth $4,273,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Olistico Wealth LLC purchased a new stake in shares of Pfizer during the second quarter valued at approximately $25,000. MFA Wealth Advisors LLC purchased a new stake in Pfizer during the 2nd quarter valued at $29,000. Creekmur Asset Management LLC bought a new stake in Pfizer in the 4th quarter worth $32,000. Trivant Custom Portfolio Group LLC increased its position in shares of Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 600 shares during the period. Finally, Financial Connections Group Inc. bought a new position in shares of Pfizer during the second quarter valued at about $34,000. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

PFE has been the topic of several recent analyst reports. UBS Group raised their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Wells Fargo & Company lifted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday, August 19th. Eight analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Stock Up 1.0 %

Shares of PFE traded up $0.29 during mid-day trading on Friday, reaching $29.01. The company had a trading volume of 37,137,599 shares, compared to its average volume of 38,496,418. The firm has a 50-day moving average price of $28.99 and a 200 day moving average price of $28.01. The company has a market capitalization of $164.39 billion, a price-to-earnings ratio of -483.50, a price-to-earnings-growth ratio of 0.98 and a beta of 0.69. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $36.29. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. During the same period in the prior year, the firm posted $0.67 EPS. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. On average, sell-side analysts forecast that Pfizer Inc. will post 2.68 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be given a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 5.79%. The ex-dividend date is Friday, July 26th. Pfizer’s dividend payout ratio (DPR) is presently -2,800.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.